Donor haplotype B of NK KIR receptor reduces the relapse risk in HLA-identical sibling hematopoietic stem cell transplantation of AML patients

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages

  Impola, Ulla ^a   Turpeinen, Hannu ^b   Alakulppi, Noora ^a   Linjama, Tiina ^a   Volin, Liisa ^c   Niittyvuopio, Riitta ^c   Partanen, Jukka ^a   Koskela, Satu ^a  

^a FRC Blood Service Research and Development ^*  (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Graft versus tumor effect; HLA; KIR; NK cells; Transplantation immunology

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR B; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; GENE; GENETIC ANALYSIS; GENOTYPING TECHNIQUE; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; ORGAN DONOR; RECURRENCE FREE SURVIVAL; SIBLING;

EID: 84935095286     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00405     Document Type: Article

References (28)

1. Warren ED., Zhang XC., Li S., Fan W, Storer BE., Chien JW., Boeckh MJ., Zhao LP., Martin PJ., Hansen JA.: Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT Blood (2012) 120:2796-2806, DOI:10.1182/blood-2012-04-347286.
2. Foley B, Felices M., Cichocki F., Cooley S., Verneris MR., Miller JS. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT) Immunological Reviews (2014) 258:45-63.
3. Velardi A: Role of KIRs and KIR ligands in hematopoietic transplantation: Current Opinion in Immunology (2008), 20:581-587 DOI: 10.1016/j.coi.2008.07.004.
4. Moretta L., Bottino C., Cantoni C., Mingari MC., Moretta A. Human natural killer cell function and receptors. Curr Opin Pharmacol.(2001)1(4):387 -91. Review.
5. Shilling HG., Young N., Guethlein LA., Cheng NW., Gardiner CM., Tyan D., Parham P. Genetic control of human NK cell repertoire. J Immunol. (2002) 1;169 (1):239-47.
6. Hsu KC., Liu XR., Selvakumar A., Mickelson E., O'Reilly RJ., Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets.J Immunol. (2002) 169:5118-29.
7. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik WD., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., Martelli MF., Velardi A. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic. Transplants Science (2002) 295, 2097 DOI: 10.1126/science.1068440.
8. Stern M., Paulussen M., Rischewski J., Tichelli A., Gratwohl A.Missing ligand model in autologous stem cell transplantation. Journal of Cancer (2008) 98, 852- 853.DOI:10.1038/sj.bjc.6604153.
9. Cooley S., Weisdorf DJ., Guethlein LA., Klein JP., Wang T., Le CT., Marsh SGE., Geraghty D., Spellman S., Haagenson MD., Ladner M., Trachtenberg E., Parham P., Miller JF.: Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia: Blood (2010) 116: 2411-2419, DOI: 10.1182/blood-2010-05-283051.
10. Kröger N., Binder T., Zabelina T., Wolschke C., Schieder H. Renges H., Ayuk F. Dahlke J. Eiermann T., Zander A.: Low Number of Donor Activating Killer Immunoglobulin-Like Receptors (KIR) Genes but not KIR-Ligand Mismatch Prevents Relapse and Improves Disease-Free Survival in Leukemia Patients After In Vivo T-Cell Depleted Unrelated Stem Cell Transplantation. Transplantation (2006) 82: 1024-1030) DOI:10.1097/01.tp.0000235859.24513.43.
11. Davies SM., Ruggieri L., DeFor T., John E. Wagner JE., Weisdorf DJ., Miller JS., Velardi A., Blazar B. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants Blood (2002)100: 3825-3827 DOI:10.1182/blood-2002-04-1197.
12. Sivula J., Volin L., Porkka K., Vettenranta K. , Itälä M., Partanen J., Turpeinen H. Killer-cell immunoglobulin-like receptor ligand compatibility in the outcome of Finnish unrelated donor hematopoietic stem cell transplantation. Transplant Immunology (2007) 18:62- 66 DOI:10.1016/j.trim.2007.03.006.
13. Dupont B, Hsu K.: Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Opinion in Immunology (2004) 16:634-643. DOI 10.1016/j.coi.2004.07.013.
14. Sivula J, Turpeinen H., Volin L., Partanen J: Association of IL-10 and IL-10Rß gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. BMC Immunology (2009), 10:24. doi:10.1186/1471-2172-10-24.
15. Turpeinen H, Volin L, Nikkinen L, Ojala P, Palotie A, Saarela J, and Partanen J. Genetic similarity of chromosome 6 between patients receiving hematopoietic stem cell transplantation and HLAmatched sibling donors. Haematologica (2009) 94:528-535. DOI:10.3324/haematol.2008.000919.
16. Denis L., Sivula J., Gourraud P.-A., Kerdudou N., Chout R., Ricard C., Moisan J.-P., Gagne K., Partanen J., Bignon J.-D.: Genetic diversity of KIR natural killer cell markers in populations from France, Guadeloupe, Finland, Senegal and Ré union: Tissue Antigens (2005) 66: 267-276, DOI: 10.1111/j.1399-0039.2005.00473.x.
17. Cooley S., Trachtenberg E., Bergemann T.L., Saeteurn K., Klein J., Le C.T., Marsh S.G.E, Guethlein L.A., Parham P., Miller J.S., Weisdorf D.J.: Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood (2009) 113: 726-732. doi:10.1182/blood-2008-07-171926.
18. Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, Oudshoorn M, Loiseau P, Dolstra H, Markiewicz M, Leffell MS, Pereira N, Kircher B, Turpeinen H, Eliaou JF, Gervais T, Laurin D, Enczmann J, Martinetti M, Thomson J, Oguz F, Santarone S, Partanen J, Siekiera U, Alessandrino EP, Kalayoglu S, Brand R, Goulmy E. Multicenter Analyses Demonstrate Significant Clinical Effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-Matched Related and Unrelated Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2013), 19(8):1244-53. DOI: 10.1016/j.bbmt.2013.06.001.
19. McCarroll SA., Bradner JE., Turpeinen H., Volin L., Martin PJ., Chilewski SD., Antin JD. , Lee SJ., Ruutu T., Storer B., Warren EH., Zhang B., Zhao LP., Ginsburg D., Soiffer RJ., Partanen J., Hansen JA., Ritz J., Palotie A., Altshuler D.: Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nature Genetics (2009) 41:12:1341-1345. DOI:10.1038/ng.490.
20. Ruggeri L., Mancusi A., Capanni M., Urbani E., Carotti A., Aloisi T., Stern M., Pende D., Perruccio K., Burchielli E., Topini F., Bianchi E., Aversa F., Martelli MF., Velardi A. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value Blood (2007) 110:433-440 DOI:10.1182/blood-2006-07-038687.
21. Stringaris K., Adams S., Marcela Uribe M., Eniafe R., Wu CO., Savani BN., Barrett JA. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukemia but Not Other Hematologic Malignancies Biol Blood Marrow Transplant (2010) 16: 1257-1264.
22. Symons, HJ., Leffell MS., Rossiter ND., Zahurak M., Jones RJ., Fuchs EJ., Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation (2010) 16: 533-542. DOI:10.1016/j.bbmt.2009.11.022.
23. Sobecks RM., Askar M., Thomas D. , Rybicki L., Kalayci M., Dean R., Avery R., Mossad S., Copelan E., Bolwell BJ. Cytomegalovirus Reactivation After Matched Sibling Donor Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant Correlates With Donor Killer Immunoglobulin-like Receptor Genotype. Experimental and Clinical Transplantation (2011) 1: 7-13.
24. Zaia JA., Sun JY., Gallez-Hawkins GM., Thao L., Oki A., Lacey SF., Dagis A., Palmer J., Diamond DJ., Forman DJ., Senitzer D. The Effect of Single and Combined Activating Killer Immunoglobulin-like Receptor Genotypes on Cytomegalovirus Infection and Immunity after Hematopoietic Cell Transplantation Biol Blood Marrow Transplant (2009) 15: 315-325 DOI:10.1016/j.bbmt.2008.11.030.
25. Cook M., Briggs D., Craddock C., Mahendra P., Milligan D., Fegan C., Darbyshire P., Lawson S., Boxall E. Moss P.: Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood (2006) 107: 1230-1232. doi:10.1182/blood-2005-03-1039.
26. Tomblyn M., Young J-A H. Michael D. Haagenson MD., Klein JP., Trachtenberg EA., Storek J., Spellman SR., Cooley S., Miller JS., Weisdorf DJ. on behalf of the CIBMTR Infection and Immune Reconstitution Working Committee. Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Biol Blood Marrow Transplant (2010) 16: 1155-1161 DOI:10.1016/j.bbmt.2010.02.024
27. McQueen K.L., Dorighi K.M., Guethlein L.A., Wong R., Sanjanwala B., Parham P.: Donor- Recipient Combinations of Group A and B KIR Haplotypes and HLA class I Ligand Affect the Outcome of HLA-Matched, Sibling Donor Hematopoietic Cell Transplantation. Human Immunology (2007) 68, 309-323. doi:10.1016/j.humimm.2007.01.01928.
28. Gagne K, Brizard G, Gueglio B., Milpied N., Herry F., Bonneville F., M-L Cheneau, Schleinitz N., Cesbron A., Gilles Follea G., Harrousseau J-L., Jean-Denis Bignon: Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol (2002) 63: 271-280.